GSK · story · 4 November – 5 November
GSK · 3 headlines from 3 outlets, from 4 November 2026 to 5 November 2026.
Canada approved Hibsago for chronic hepatitis B and granted priority review for a submission.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Dealroom is the largest at 10.0, ahead of BioSpace (10.0).
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Dealroom | 10.0 |
| BioSpace | 10.0 |
| PR Newswire Canada | 10.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Dealroom | 1 | +10.0 |
| BioSpace | 1 | +10.0 |
| PR Newswire Canada | 1 | +10.0 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Canadian approval of a first-of-kind hepatitis B therapy. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Approval of new hepatitis B therapy, a significant milestone |
| +10.0 | Fast-track regulatory review for promising hepatitis B drug in Canada |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.